For the past month, local basketball programs have teamed up to raise awareness and spread hope for 9-year-old Autumn and ...

Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...

The study will look to identify early genetic changes in the cells lining the mouth of patients with Fanconi anemia (FA) ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twelve research firms that are currently covering the stock, ...

Jennison Associates LLC lifted its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 72.6% during the 4th quarter, according to its most recent filing with the ...

Fanconi anemia (FA) is a rare genetic disorder characterized by defective DNA repair, leading to hematopoietic stem cell (HSC) dysfunction and bone marrow failure. Replication stress, which ...

Patients in the EU with Fanconi anaemia (FA) could soon have the first gene therapy option for the disorder, as the EMA starts a review of Rocket Pharma’s RP-L102 candidate. FA is an inherited ...

Helen Jackson's toddler, misdiagnosed with flu, was later found to have acute lymphoblastic leukemia after her condition worsened. Gracie, 2, underwent immediate treatment, including chemotherapy ...